Revance Therapeutics (RVNC) Misses Q4 EPS by $1.08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
February 28, 2023 4:06 PM ESTQ4 and full year 2022 total revenue of $49.9 million and $132.6 million, a YoY increase of 92% and 70%, respectively. Q4 and full year 2022 RHA® Collection revenue of $34.8 million and $107.2 million, a YoY increase of 46% and 51%, respectively. DAXXIFY® Q4 PrevU revenue of $11.0 million, with commercial launch to begin late March 2023. PDUFA date for DAXXIFY® for the treatment of cervical dystonia of August 19, 2023. Appointed Dr. Vlad Coric, M.D., Chairman and CEO of Biohaven, to the companys Board of Directors. Conference call and webcast today at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS... More
